ONCOLOGY PORTFOLIO - Approved Products & Pipeline

INN /COMPOUND	CLASS	TARGET & MODALITY	INDICATION OR DISEASE
Vinorelbine	**Chemotherapy**	Vinca Alkaloid	Advanced **BREAST CANCER** as monotherapy or in combination with other agents
		Vinca Alkaloid	Advanced **NSCLC** as monotherapy or in combination with other chemotherapies
		Vinca Alkaloid	Adjuvant treatment of **NSCLC** in combination with platinum-based chemotherapy
Vinflunine	**Chemotherapy**	Vinca Alkaloid	Advanced or metastatic transitional-cell carcinoma of the **UROTHELIAL** tract
Neratinib[1]	**Targeted therapy**	Pan-HER inhibitor	HER2 amplified / overexpressed / HR+ early **BREAST CANCER** (extended adjuvant post trastuzumab based therapy)
Tabelecleucel[2]	**Cell therapy**	Allogeneic T-cell immunotherapy	Epstein-Barr virus associated post-transplant lymphoproliferative disease **(EBV + PTLD)**
Encorafenib[3] / **Binimetinib**[4] (± other agents)	**Targeted therapy**	BRAF inhibitor + MEK inhibitor	Unresectable or metastatic *BRAF*^{V600}-mutant **MELANOMA**
		BRAF inhibitor	Metastatic *BRAF*^{V600E}-mutant **CRC** after prior systemic therapy
		BRAF inhibitor + MEK inhibitor	Metastatic *BRAF*^{V600E}-mutant **NSCLC**[5]
		BRAF inhibitor	Previously treated metastatic *BRAF*^{V600E}-mutant **CRC** in Chinese population - NAUTICAL study
		BRAF inhibitor + MEK inhibitor	Metastatic *BRAF*^{V600E}-mutant **NSCLC** in Chinese population - OCEAN study
Exarafenib[6]	**Targeted therapy**	Pan-RAF small molecule inhibitor	*NRAS* mutant **MELANOMA** and other *BRAF* / *NRAS* mutant solid tumors
PFL-721 / **STX-721**[7]	**Targeted therapy**	Mutant-selective EGFR-exon20 small molecule inhibitor	**NSCLC** with *EGFR* exon 20 insertion mutation
PFL-241 / **STX-241**[7]	**Targeted therapy**	Mutant-selective 4th generation EGFR small molecule inhibitor	**NSCLC** with *EGFR* exon 19/21 + C797S mutations
PFL-002 / **VERT-002**[8]	**Targeted therapy**	Anti-cMET antibody degrader	**NSCLC** / solid tumors with mutations or amplification of *MET*
Not-disclosed[9]	**Targeted therapy**	Multiple targets	**ONCOLOGY**



*Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation).
1.Commercialized in partnership with Puma Biotechnology. **2.**Commercialized in partnership with Atara Biotherapeutics. **3.**Encorafenib + cetuximab is approved for *BRAF*^{V600E}-mutant mCRC, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic *BRAF*-mutant melanoma, in adult patients. **4.**Developed and launched in partnership with Array Biopharma (partnered with Pfizer since 2020). **5.**Clinical development under Pfizer sponsorship. **6.**Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. **7.**Co-development in partnership with Scorpion Therapeutics Inc., Boston, USA. The sponsor of these studies could be Pierre Fabre Medical Care or Scorpion Therapeutics Inc. **8.**Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. **9.**Discovery partnership with Vernalis Lt and RedRidge Bio.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications.
Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

HQ--03-24-2400065 – V8 – Elaboration date: March 2025

LABORATOIRES
Pierre Fabre